Vistagen Therapeutics, Inc.
For the period ended Sep 30, 2025. Filed Nov 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 13, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
On November 12, 2025 Shawn K. Singh, JD, age 62, our President and Chief Executive Officer, was appointed to act, on a temporary basis, as our interim principal financial and accounting officer, pending the completion of our ongoing search for a successor to our previous Chief Financial Officer. The information required by Items 401(b), (d), (e) and Item 404(a) of Regulation S-K is incorporated by reference from our definitive proxy statement on Schedule 14A filed with the SEC on July 28, 2025.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.